%0 English Abstract
%T [The Prognostic Value of Del(1p32) in Patients with Newly Diagnosed Multiple Myeloma].
%A Guo R
%A Shen XX
%A Xia Y
%A Jin YY
%A Li JY
%A Chen LJ
%A Qiu HR
%J Zhongguo Shi Yan Xue Ye Xue Za Zhi
%V 32
%N 3
%D 2024 Jun
%M 38926965
暂无%R 10.19746/j.cnki.issn.1009-2137.2024.03.017
%X <B>OBJECTIVE: </B>To analyze the prognostic value of del(1p32) in patients with newly diagnosed multiple myeloma (MM).<BR><B>METHODS: </B>The clinical data of 341 newly diagnosed MM attended in Jiangsu Province Hospital were retrospective analyzed. Clinical characteristic combined with genetic features, especially del(1p32), were analyzed for survival and prognostic of patients.<BR><B>RESULTS: </B>Among the 341 patients with newly diagnosed MM, 24(7.0%) patients were del(1p32) positive. The progression-free survival (PFS) and overall survival (OS) were significantly shorter in MM patients with del(1p32) than those without del(1p32) (PFS: P < 0.001;OS: P < 0.001). The COX proportional-hazards model showed that del (1p32) was an independent risk factor for PFS and OS of patients with MM. The patients with both 1q21 gain/amplification and del(1p32), as "double-hit chromosome 1", have worse prognosis than those with only 1q21 gain/amplification or only del(1p32) (PFS: P < 0.001; OS: P < 0.001).<BR><B>CONCLUSIONS: </B>Del(1p32) is an independent risk factor for PFS and OS of patients with MM. Del(1p32) detection should be widely used in the prognostic analysis for newly diagnosed MM patients.<BR><B>UNASSIGNED: </B>1p32缺失在初诊多发性骨髓瘤患者中的预后意义.<BR><B>UNASSIGNED: </B>分析1p32缺失在初诊多发性骨髓瘤（MM）患者中的预后意义。.<BR><B>UNASSIGNED: </B>回顾性分析2017年4月至2022年12月在江苏省人民医院就诊的341例初诊MM患者的临床资料，结合遗传学特征，尤其是1号染色体遗传学异常中的1p32缺失，分析患者的生存及预后。.<BR><B>UNASSIGNED: </B>341例初诊MM患者中，1p32缺失阳性患者占7.0%（24/341），伴有1p32缺失的MM患者的无进展生存（PFS）显著短于不伴有1p32缺失患者（P < 0.001），总生存（OS）同样更短（P < 0.001）。COX风险回归分析显示，1p32缺失是影响MM患者生存的独立危险因素。同时伴有1q21扩增和1p32缺失，即“1号染色体双打击”MM患者的PFS及OS相较于仅有1q21扩增或仅有1p32缺失MM患者更差（PFS：P < 0.001；OS：P < 0.001）。.<BR><B>UNASSIGNED: </B>1p32缺失是影响MM患者PFS及OS的独立危险因素，1p32缺失应广泛应用于初诊MM的预后判断。.